Stay Up To Date ON The Latest Cellvax News
December 1, 2020
Cellvax has obtained an EuroNanoMed project which will start in January 2021. Project Title: Reactivation of antitumor immune responses in gliomas using nanotechnology based targeted delivery. Glioblastoma (GBM) is the most common and aggressive brain cancer for which the current therapy is ineffective. Our project will validate the strategy of therapeutic modulation of immune cells in the tumor microenvironment to improve immunotherapy and provide a smart immunomodulatory nanosystem for future clinical applications.
October 1, 2020
Constantly, Cellvax is strengthening its capabilities and expertise for preclinical studies. In particular in orthopedic (Osteoarthritis) models, Cellvax’s team is continuously trained and updated by veterinary surgeon, diplomate from the European College of Veterinary Surgeon (ECVS) and PhD.
September 1, 2020
Since September 2020, Cellvax is able to perform in vitro tests to screen and validate anti-osteoarthritis drug candidates.
July 1, 2020
Since July 2020, Cellvax has moved to Villejuif Bio Park which is closely located in a scientific and medical privileged area, between two large French hospitals, IGR (Institut Gustave Roussy) which is the largest anticancer center in France and in Europe, and the hospital Paul Brousse.
June 1, 2020
Since July 2018, Cellvax has performed large GLP toxicology / Biodistribution studies. The studies were performed by Cellvax team and inspected in 2020 by French authority ANSM. The study was declared in conformity to GLP guidelines in June 2020. Consequently, the planned clinical trials of our client start as planned.
April 1, 2020
Cellvax is proud to announce it large European collaborative project H2020 officially starts since April 1st, 2020.
November 11, 2019
Cellvax is present at BIO-EUROPE, 25TH Annual International Partnering Conference, November 11-13, Hamburg, Germany.
October 31, 2019
Cellvax is present at LES ASSISES POLEPHARMA DE L’INNOVATION, October 31, ROUEN, France.
May 02, 2019
BIOTECHFINANCES: CELLVAX SIGNS TWO PARTERSHIPS TO DIVERSIFY ITS MODELS (FR).
April 16, 2019
FRENCH BIOTECH CELLVAX IS NOW ABLE TO PROPOSE PRECLINICAL STUDIES IN LARGE ANIMALS.
LA BIOTECH FRANÇAISE CELLVAX ANNONCE QU’ELLE ELARGIT SA GAMME DE MODELES ANIMAUX.
April 1, 2019
Cellvax is proud to announce a Strategic Partnership with two Chinese CRO. The purpose of this strategic partnership is to better serve their clients in a more efficient way and in the whole world such as preclinical trials in small and large animals: Monkeys, Beagle dogs and Pigs, diversified preclinical models, clinical trials, product registrations in China for European clients, better understanding of European markets for Chinese clients, etc.
Ultimately, three companies will strengthen their efforts to conduct joint preclinical studies and get the clients’ full satisfactions. Thus, a perfect complementarity exists among the three partners in China and in France.
February 4, 2019
As part of the continuous development, Cellvax has implemented two new rooms of animal house type A2 equipped with new and qualified materials ( Mainly: ventilated cabinets (120 cages capacity), centrifuge, balances, Biological Safety Cabinet, Large Autoclave, Freezer -80°C ). Photos are presented in this attached document A2 New Animal House Cellvax.
November 5, 2018
Cellvax is present at BIO-EUROPE, 24TH Annual International Partnering Conference, November 5-7, Copenhagen, Denmark.
September 28, 2018
Cellvax is proud to announce its first COST Action CA17140. The Action Title is Cancer nanomedicine from the bench to the bedside. The kick-off meeting was held in Brussels, Belgium on 28 September 2018.
The COST Association is committed to upholding its Excellence and Inclusiveness policy in order to increase support towards young researchers from Inclusiveness Target Countries (ITC). COST have developed two measures under the newly established COST Academy2 to boost skills and empower career development. The COST Academy was launched in September 2017 as an initiative following the COST strategy and concept of growing people and ideas. The Academy offers training, workshops and mentoring for COST Action participants.
May 17, 2018
Cellvax is present at MEET2WIN, Oncology Business Convention, May 17-18, Bordeaux, France.
May 15, 2018
Cellvax is present at Biomed, 17 th MIXii-BIOMED 2018 Conference and Exhibition, May 15-17, Tel Aviv, Israel.
May 3, 2018
Cellvax is present at Swiss Biotech Day, Life Science Conference 2018, May 3, Basel, Switzerland.
March 22, 2018
Recently, Cellvax has successfully obtained a new European collaborative project “EUROSTARS-2”. After a strict scientific, technical selection and the impact, our project has finally been selected for funding. This project will start in March 2018. The consortium involves two French partners (Cellvax and INSERM group) and two Dutch partners.
March 12, 2018
Cellvax is present at BIO-Europe spring, 12TH Annual International Partnering Conference, March 12-14, Amsterdam, Netherlands.
November 28, 2017
Cellvax is present at BioFIT, A 360° approach to source early-stage innovations in Life Sciences, November 28-29, Strasbourg, France.
November 06, 2017
Cellvax is present at BIO-Europe, 23 RD Annual International Partnering Conference, November 06-08, Berlin, Germany.
October 03, 2017
Cellvax is present at Biotech Outsourcing Strategies (BOS) 2017 Discovery, Early Development & Clinical Operations Outsourcing, London, UK.
March 20, 2017
Cellvax is present at BIO-Europe Spring 2017, 11th International Partnering Conference, March 20-22, Barcelona, Spain.
May 08, 2017
Cellvax is present at Biotrinity 2017, Europe’s Leading Biopartnering and Investment Conference, May 08-10, London, UK.
May 11, 2017
Cellvax is present at MEET2WIN 2017, Oncology Business Convention, May 11-12, Bordeaux, France.